The Healing Project wishes to congratulate Dr. Mark Bear’s team at MIT in demonstrating targeted gene therapeutics potential in curing disease. A team scientists led by Dr. Bear have been able to correct many of the abnormalities associated with fragile X syndrome in a rodent model. There is currently no treatment or therapy for fragile X syndrome. Fragile X syndrome is caused by loss of the gene for "fragile X mental retardation protein" (FMRP). It affects about 100,000 people in the United States and is also a leading known genetic cause of autism.
Based on these results, human trials focused on mGluR5 should begin next year by Seaside Therapeutics. The company was co-founded by Dr. Bear and pharmaceutical industry veteran, Randy Carpenter, MD.
Based on these results, human trials focused on mGluR5 should begin next year by Seaside Therapeutics. The company was co-founded by Dr. Bear and pharmaceutical industry veteran, Randy Carpenter, MD.
No comments:
Post a Comment